Clinical Trials

282 enrolled

Solid Tumors

NCT05203172 2026-03-18

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

46 enrolled

Solid Tumors

NCT05689853 2026-03-18

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

87 enrolled

Solid Tumor, Adult

NCT06233942 2026-03-18

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

308 enrolled

Advanced Solid Tumor

NCT06248411 2026-03-18

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

189 enrolled

Advanced or Metastatic Solid Tumors

NCT06487858 2026-03-18

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

75 enrolled

Solid Tumor

NCT06585488 2026-03-18

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

GastrointestinalOther solid neoplasmThoracic

514 enrolled

Metastatic Solid Tumors

NCT07480681 2026-03-18

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

138 enrolled

Advanced/Metastatic Solid Tumors

NCT05155332 2026-03-17

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

190 enrolled

Solid Tumors

NCT06056024 2026-03-17

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Phase 1 Completed

47 enrolled

Solid Tumor, KRAS Mutation

NCT06581432 2026-03-17

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

430 enrolled

Solid Tumours

NCT06960395 2026-03-17

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

450 enrolled

Solid Tumor Malignancies

NCT07477743 2026-03-17

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

331 enrolled

Phase 1/2 Active not recruiting

Advanced Solid Tumor Cancer

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

713 enrolled 1 FDA

KRAS p.G12C Mutant Advanced Solid Tumors

NCT07475559 2026-03-16

JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors

42 enrolled

Advanced Solid Tumor Malignancies

NCT05571839 2026-03-13

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

DermatologicGastrointestinalOther solid neoplasmThoracic

41 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05957536 2026-03-13

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

128 enrolled

HER-2 Positive Advanced Solid Tumors

NCT06307795 2026-03-13

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

63 enrolled

Locally Advanced or Metastatic Solid Tumors

NCT06391918 2026-03-13

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

Phase 1 Terminated

37 enrolled

Solid Tumor, Adult

NCT06736704 2026-03-13

SNV4818 in Participants With Advanced Solid Tumors

320 enrolled

Advanced Solid Tumors

NCT06892379 2026-03-13

A Study of HS-20110 in Participants With Advanced Solid Tumors

475 enrolled

Solid Tumors

NCT07207707 2026-03-13

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

78 enrolled

Solid Tumor Malignancies

NCT07223125 2026-03-13

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

360 enrolled

Advanced-stage Solid Tumors

NCT07300943 2026-03-13

Study in Advanced Solid Tumor Patients

306 enrolled

Phase 1/2 Not yet recruiting

Advanced Solid Tumor

NCT07469774 2026-03-13

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

111 enrolled

Phase 1/2 Active not recruiting

Locally Advanced or Metastatic Solid Tumors

NCT06057922 2026-03-12

A Study YL201 in Patients With Selected Advanced Solid Tumors

990 enrolled

Advanced Solid Tumor

NCT06598800 2026-03-12

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

87 enrolled

Advanced Solid Tumor

NCT07229638 2026-03-12

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

70 enrolled

Solid Tumor

NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

14 enrolled

TP53 Y220C Mutation

NCT07466160 2026-03-12

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

280 enrolled

Solid Tumor

NCT07467629 2026-03-12

QLS5212 for Participants With Advanced Solid Tumors

100 enrolled

Solid Tumor Cancer

NCT04261413 2026-03-11

Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

16 enrolled

Solid Tumors

NCT04939610 2026-03-11

LuMIERE

222 enrolled

Solid Tumor

NCT06234397 2026-03-11

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

245 enrolled

Advanced or Metastatic Solid Tumors

NCT07111546 2026-03-11

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

140 enrolled

Advanced Solid Tumour

NCT07196644 2026-03-11

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

125 enrolled

Solid Tumors Harboring MET Amplification

NCT07417189 2026-03-11

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

401 enrolled

Solid Tumors, Adult

NCT05735366 2026-03-10

A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

22 enrolled

Solid Tumor

NCT05781048 2026-03-10

A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors

56 enrolled

Advanced Solid Tumors

NCT06499350 2026-03-10

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

33 enrolled

Phase 1/2 Not yet recruiting

Advanced Malignant Solid Tumors

NCT07459998 2026-03-10

SKB103 for Injection in Advanced Solid Tumors

277 enrolled

Phase 1/2 Not yet recruiting

Advanced Solid Tumors

NCT07460375 2026-03-10

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

191 enrolled

Advanced Solid Tumors

NCT07462442 2026-03-10

Study of QLS5308 in Patients With Advanced Solid Tumors

192 enrolled

Metastatic Solid Tumors

NCT05514132 2026-03-09

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

14 enrolled

Advanced Solid Tumours

NCT07069062 2026-03-09

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors

261 enrolled

Solid Tumor

NCT07141706 2026-03-09

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

233 enrolled

Advanced/Metastatic Solid Tumors

NCT07331155 2026-03-09

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

110 enrolled

Phase 1/2 Active not recruiting

Advanced Solid Tumour

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

410 enrolled

Select Advanced Solid Tumors

NCT04589845 2026-03-06

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

920 enrolled 1 FDA